Written Question·Department of Health and Social Care·UIN 120764

Blood Cancer: Immunotherapy

Tabled: 16 March 2026

Answered: 19 March 2026

Named Day

Question

Mr Clive Betts

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of the removal of access to a CAR-T therapy for mantle cell lymphoma on patients; and if his Department will consider learnings from

Answer

Dr Zubir Ahmed

The National Institute for Health and Care Excellence (NICE) is re-evaluating brexucabtagene autoleucel following managed access through the Cancer Drugs Fund to determine whether it should be recommended for routine National Health Service funding. NICE’...

ⓘ

This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 120764) →